osteoporosis
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically
June 19, 2023Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics
US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …
Theramex releases Vitamin D gel aimed at women
May 5, 2021Research and Development Theramex, osteoporosis, pharma, pharma news, vitamin d
Theramex has launched a new gel for Vitamin D deficiency, in the hope that it will particularly treat women experiencing …
Theramex launches osteoporosis drug Livogiva in Europe
January 18, 2021Sales and Marketing Theramex, osteoporosis
Theramex, a London-headquartered pharmaceutical company dedicated to women’s health, has launched osteoporosis medicine Livogiva to patients in Europe for the …
FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture
October 9, 2019Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma
The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds
April 8, 2019Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
Amgen and UCB’s Evenity approved in Japan for osteoporosis
January 9, 2019Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma
Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …
FDA refuses approval of Amgen osteoporosis drug
July 17, 2017Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical
Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …
Osteoporosis drugs potentially causing long-term bone weakness
March 2, 2017Research and Development osteoporosis
Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from …
MSD drops osteoporosis trial drug due to stroke risk
September 5, 2016Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke
MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …
Further positive trial results boost Amgen and UCB’s romosozumab
March 21, 2016Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval
Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
